Mirada Medical Announces the Appointment of Karsten Damgaard-Iversen as Non-Executive Chairman

OXFORD, UK–(Marketwire – July 12, 2010) –  Mirada Medical Limited (“Mirada” or “the Company”)

Oxford, UK and Ohio, US, 12 July 2010: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that Karsten Damgaard-Iversen has joined the Board of the Company as Non-Executive Chairman. 

Karsten Damgaard-Iversen is an internationally accomplished business professional with more than 30 years global experience of working within the healthcare imaging industry. He is a proven leader with a successful track record in operational and strategic management positions within small, medium and large medical imaging and healthcare technology companies. Mr. Damgaard-Iversen, aged 54, combines strong business acumen with in-depth technical and medical knowledge and has served in executive positions such as Managing Director and Chief Group Executive of Toshiba Medical Systems Europe BV, Managing Director of Toshiba Medical Systems (UK) Ltd., Vice President of International Operations of Fisher Imaging Corporation and Director of Sales & Marketing of Storz Medical AG. Mr. Damgaard-Iversen has also been a direct contributor to the invention and development of specific laser and x-ray based medical products. He holds an MBA from Emory University and a BSc in electronic engineering from Copenhagen University College.

In addition to his role as Chairman at Mirada Medical, Mr. Damgaard-Iversen is the founder and director of Disease Control Innovations Medical BV, a Dutch company engaged in product and EU business development of new medical technology that encompass innovative solutions to disease management and diagnosis. DCI Medical currently supports SonoCine Corporation, a privately held US inventor of automated whole breast ultrasound (AWBU) for screen detection of mammograhically occult breast cancer, and US quoted Imaging Diagnostic Systems, a pioneer in laser optical imaging systems.

Commenting on the appointment of the new Chairman, Hugh Bettesworth, CEO of Mirada Medical, said: “I am delighted that Karsten has chosen to join Mirada Medical as Chairman and that we have been able to attract such international talent from the medical imaging industry to our Board. Karsten’s experience in product development, together with his strategic and operational leadership, will provide Mirada with excellent guidance and steering as we continue to grow and prosper in the global oncology imaging marketplace.”

Commenting on his appointment as Chairman of the Board of Mirada Medical, Mr. Damgaard-Iversen said: “I am extremely impressed by Mirada’s innovative solutions for oncology disease management and cross modality decision support systems and I hope to be able to make a significant contribution to the growth and development of the Company. I look forward to working with the team at Mirada and applying my experience and know-how from the medical imaging arena to guide and support the future success of Mirada.” 

About Mirada Medical

Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with an enhanced software package for the quantification of images, typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.